High rates of ARID1A mutations were observed in 46–57% of ovarian clear cell carcinomas, 30% of ovarian endometrioid carcinomas and 40% of uterine endometrioid carcinomas [15,47,48]. This evidence concerns the gene ARID1A and endometrial endometrioid adenocarcinoma.